SEC Form 4 · accession 0001209191-16-150891
CORCEPT THERAPEUTICS INC · CORT
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Patrick G Enright
Director · 10% Owner
Period of report
Nov 15, 2016
Accepted (ET)
Nov 17, 2016 · 4:36 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001088856
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1,F2 | Nov 15, 2016 | S | 154,359 | $9.5534 | D | 14,362,573 | I | By LVP |
| Common StockF1,F3 | Nov 15, 2016 | S | 3,094 | $9.5534 | D | 191,864 | I | By LCA |
| Common StockF4,F2 | Nov 16, 2016 | S | 17,052 | $9.5087 | D | 14,345,521 | I | By LVP |
| Common StockF4,F3 | Nov 16, 2016 | S | 342 | $9.5087 | D | 191,522 | I | By LCA |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Reflects sales of common stock executed in multiple transactions at prices ranging from $9.5000 to $9.7200. The price reported reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, Corcept Therapeutics Incorporated or a security holder of Corcept Therapeutics Incorporated full information regarding the number of shares and prices at which the sales were effected..
- F2Reflects transactions and holdings of shares of common stock of the Issuer held of record by Longitude Venture Partners, L.P. ("LVP"). Patrick G. Enright is a managing member of Longitude Capital Partners, LLC ("Longitude Capital"), the sole general partner of LVP. Mr. Enright serves on the Board of Directors of the Issuer as the nominee of LVP. Mr. Enright disclaims beneficial ownership of the securities of the Issuer held of record by LVP, except to the extent of his pecuniary interest therein.
- F3Reflects transactions and holdings of shares of common stock of the Issuer held of record by Longitude Capital Associates, L.P. ("LCA"). Patrick G. Enright is a managing member of Longitude Capital, the sole general partner of LCA. Mr. Enright disclaims beneficial ownership of the securities of the Issuer held of record by LCA, except to the extent of his pecuniary interest therein.
- F4Reflects sales of common stock executed in multiple transactions at prices ranging from $9.5000 to $9.5450. The price reported reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, Corcept Therapeutics Incorporated or a security holder of Corcept Therapeutics Incorporated full information regarding the number of shares and prices at which the sales were effected.